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Messenger-Mediated Enhancement of TRPV1 Activity
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Abstract
Glucocorticoids influence vagal parasympathetic output to the viscera via mechanisms that include modulation of
neural circuitry in the dorsal vagal complex, a principal autonomic regulatory center. Glucocorticoids can modulate
synaptic neurotransmitter release elsewhere in the brain by inducing release of retrograde signalling molecules. We
tested the hypothesis that the glucocorticoid agonist dexamethasone (DEX) modulates GABA release in the rat
dorsal motor nucleus of the vagus (DMV). Whole-cell patch-clamp recordings revealed that DEX (1-10 µM) rapidly
(i.e. within three minutes) increased the frequency of tetrodotoxin-resistant, miniature IPSCs (mIPSCs) in 67% of
DMV neurons recorded in acutely prepared slices. Glutamate-mediated mEPSCs were also enhanced by DEX (10
µM), and blockade of ionotropic glutamate receptors reduced the DEX effect on mIPSC frequency. Antagonists of
type I or II corticosteroid receptors blocked the effect of DEX on mIPSCs. The effect was mimicked by application of
the membrane-impermeant BSA-conjugated DEX, and intracellular blockade of G protein function with GDP βS in the
recorded cell prevented the effect of DEX. The enhancement of GABA release was blocked by the TRPV1
antagonists, 5’-iodoresiniferatoxin or capsazepine, but was not altered by the cannabinoid type 1 receptor antagonist
AM251. The DEX effect was prevented by blocking fatty acid amide hydrolysis or by inhibiting anandamide transport,
implicating involvement of the endocannabinoid system in the response. These findings indicate that DEX induces an
enhancement of GABA release in the DMV, which is mediated by activation of TRPV1 receptors on afferent
terminals. The effect is likely induced by anandamide or other ‘endovanilloid’, suggesting activation of a local
retrograde signal originating from DMV neurons to enhance synaptic inhibition locally in response to glucocorticoids.
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Introduction
Parasympathetic autonomic control of most thoracic and
abdominal viscera is accomplished by neurons in the medullary
dorsal vagal complex. The dorsal vagal complex consists of
area postrema, the nucleus tractus solitarius (NTS), and the
dorsal motor nucleus of the vagus (DMV). Axons of
preganglionic motor neurons in the DMV project throughout
most of the gastrointestinal (GI) tract and other
subdiaphragmatic viscera [1], as well as contributing to
innervation of thoracic organs. Neurons of the DMV exhibit
regular action potential firing [2,3]. This makes the neurons
susceptible to small changes in membrane potential induced by
synaptic currents. This is especially true for inhibitory
GABAergic inputs, which have a large influence on DMV
neuron activity and parasympathetic output to the viscera [4].
In addition to well-described feedback effects on the
hypothalamo-pituitary axis [5–7], stress and glucocorticoid
hormones have long been known to alter autonomic function by
modulating central autonomic circuitry. Glucocorticoid
receptors are located in the dorsal vagal complex [8], including
both the NTS and DMV, suggesting actions on central
parasympathetic circuits. Central infusion of the glucocorticoid
agonist dexamethasone (DEX) increases food intake, body
weight, and insulin output, and promotes insulin resistance in
rats [9]. These effects are prevented by vagotomy, suggesting
glucocorticoid-mediated modulation of central parasympathetic
circuits. Indeed, glucocorticoid agonists appear to act within the
vagal complex to rapidly alter various autonomic functions
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related to gastrointestinal and cardiovascular control [10–13],
possibly via GABA receptor-dependent effects [13], but the
cellular mechanisms underlying these responses are unknown.
Rapid glucocorticoid actions on neuroendocrine or
autonomic output [13–15] suggest potentially non-genomic
effects in central autonomic circuits. In hypothalamic
neuroendocrine and preautonomic neurons, glucocorticoids act
on putative membrane-associated receptors in to rapidly
stimulate the retrograde local release of endogenous
cannabinoids and possibly other retrograde messengers, which
in turn modulate afferent synaptic transmission [16–18].
Evidence for rapid cellular responses to activation of a somatic
glucocorticoid receptor has also been shown in hippocampal
cell cultures [19], and glucocorticoid receptors associated with
neuronal membranes have been identified anatomically in the
rat lateral amygdala [20].
Endocannabinoids released by glucocorticoid receptor
activation or other means tend to regulate synaptic
transmission by serving as retrograde messengers that are
released from cell membranes and bind to receptors on
afferent synaptic terminals [21–23]. One of these retrograde
signaling molecules, anandamide, is synthesized in neurons of
the vagal complex [24], and exogenously applied anandamide
acts as an agonist at both cannabinoid type 1 (CB1) receptors
and transient receptor potential vanilloid type 1 (TRPV1) on
synaptic terminals to modulate inhibitory synaptic input to DMV
neurons [25,26]. TRPV1 receptors are expressed in nodose
ganglion cells [27] and are localized in primary viscerosensory
afferent terminals in the DVC, where their activation modulates
glutamate release onto NTS neurons [28,29]. Neurons in the
NTS also express TRPV1 mRNA [30], and modulation of
GABAergic synapses in the DMV by TRPV1 agonists is
mediated in large part through heterosynaptic activation of
glutamate release [25], suggesting that terminals of NTS
neurons may also contain TPRV1 receptors. The effects of
anandamide released endogenously after strong depolarization
includes CB1 receptor activation [31], but the potential for
glucocorticoid-mediated endocannabinoid release has never
been established in the vagal complex. We therefore
investigated the effects of glucocorticoid activation in the rat
DMV, testing the hypothesis that glucocorticoids exert rapid
effects via a retrograde messenger-mediated modulation of
inhibitory synaptic input to DMV neurons.
Methods
Ethics statement
All procedures were performed on adult male Sprague-
Dawley rats (Harlan, Indianapolis, IN) in accordance with NIH
Guidelines for the care and use of animals in research and
were approved by the University of Kentucky (IACUC numbers
01063M6006; 2008-0378) and Tulane University (IACUC
number 0146-1-03-089) Animal Care and Use Committees.
Brainstem slice preparation
Transverse brainstem slices were prepared from male
Sprague-Dawley rats (Harlan), 4-8 weeks of age as previously
described [25]. Rats were deeply anesthetized by halothane or
isoflurane inhalation to effect and killed by rapid decapitation
while anaesthetized. Brains were rapidly removed and
immersed in ice-cold (0-4 oC), oxygenated (95% O2-5% CO2)
artificial cerebrospinal fluid (ACSF) containing (in mM): 124
NaCl, 3 KCl, 26 NaHCO3, 1.4 NaH2PO4, 11 mM glucose, 1.3
CaCl2, and 1.3 MgCl2, pH = 7.3-7.4, with an osmolality of
290-310 mOsm/kg. Transverse brainstem slices (350-400 µm)
containing the DVC were made using a vibrating microtome
(Vibratome Series 1000; Technical Products Intl., St. Louis,
MO). Slices were transferred to a recording chamber mounted
on a fixed stage under an upright microscope (Olympus
BX51WI; Melville, NY).
Whole-cell recording
Neurons in the DMV were visually targeted for whole-cell
patch-clamp recording under a 40x water immersion objective
using infrared differential interference contrast (IR–DIC) optics
(Olympus). Recording pipettes (2-4 MΩ open tip resistance)
were filled with a solution containing (in mM): 130 Cs+-
gluconate, 1 NaCl, 5 EGTA, 10 HEPES, 1 MgCl2, 1 CaCl2, 3
KOH, 2-4 Mg-ATP; pH=7.2, adjusted with 5 M CsOH. Neurons
were voltage-clamped in the presence of tetrodotoxin (TTX; 1
µM) at -10 mV or -70 mV to assess miniature IPSCs (mIPSCs)
or mEPSCs, respectively. As previously reported [2,25,32–34],
the large outward synaptic currents recorded at -10 mV
exhibited rapid 10-90% (~1 ms) rise time, exponential decay,
were blocked by GABAA receptor antagonists (n=5), and
reversed near the Cl- eqilibrium potential (~-80 mV); they were
therefore considered to be GABAergic mIPSCs. Inward
currents recorded at a holding potential of -70 mV also
exhibited a rapid rise time and exponential decay and were
blocked by kynurenic acid (n=5); they were considered to be
glutamatergic mEPSCs. Electrophysiological signals were low
pass filtered at 2-5 kHz, recorded using an Axopatch 700B
amplifier (Axon Instruments, Union City, CA) and pClamp 10.2
software (Axon Instruments). IPSC frequency and amplitude
were analyzed offline using Clampfit 10.2 and MiniAnalysis
(Synaptosoft, Decatur, GA).
Drug application
All experiments were performed with TTX (1 µM; Tocris) in
the ACSF to block action potential-dependent synaptic activity;
kynurenic acid (1 mM; Sigma) was added in some experiments
to block ionotropic glutamate receptors. Water-soluble
dexamethasone (DEX; Sigma) was bath applied for 3-10
minutes at a final concentration of 1-10 µM. Bovine serum
albumen (BSA)-conjugated dexamethasone (Steraloids Inc.,
Newport, RI) was dissolved in the ACSF and bath applied for
3-10 minutes at a final concentration of 10 µM. Inhibitors of
anandamide uptake O-2093 (10 µM) or OMDM-2 (10 µM), and
the selective TRPV1 receptor antagonists 5´-iodoresiniferatoxin
(5’-iRFT; 1 µM; Tocris) or capsazepine (1 µM; CPZ; Tocris)
were first dissolved in ethanol and diluted to final concentration
in ACSF (final concentration of ethanol <0.01% by volume).
The CB1 receptor antagonist AM251 (10-20 µM; Tocris), the
inhibitor of fatty acid amide hydrolase (FAAH), URB-597 (10
µM; Sigma), and the glucocorticoid receptor antagonists
mifepristone (1 µM; Sigma) and spironolactone (1 µM; Sigma)
Dexamethasone-Induced Retrograde Signaling in DMV
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were dissolved in DMSO (final DMSO concentration <0.01% by
volume). Reuptake blockers and receptor antagonists were
bath applied for at least 10 min prior to agonist application. The
nonhydrolyzable guanylyl nucleotide GDP-β-S (500 µM;
Sigma-Aldrich) was included in the pipette solution in some
experiments to prevent G protein-coupled receptor activity in
the recorded neuron.
Data analysis
The effects of DEX on mIPSC or mEPSC frequency and
amplitude were analyzed within a recording using the intra-
assay Kolmogorov-Smirnov test (i.e., K–S test; a
nonparametric, distribution-free, goodness-of-fit test for
probability distributions). Pooled results from responding
neurons were analyzed using a paired two-tailed Student’s t-
test. For all analyses, P<0.05 was considered significant.
Values are reported as the mean ± SEM.
Results
Dexamethasone increased mIPSC frequency in DMV
neurons
The effect of DEX on mIPSCs was examined in DMV
neurons in the presence of TTX (1 µM). Neurons were voltage-
clamped at -10 mV using Cs+ in the recording pipette to block
voltage-dependent K+ channels and consequently improve
quality of the voltage clamp [26,35]. Application of different
concentrations of DEX (1-10 µM) resulted in a concentration-
related increase in the frequency of mIPSCs (Figure 1E). All
neurons were tested by the intra-assay K–S test to determine if
DEX induced a significant change in mIPSC frequency within a
recording, and neurons with a significant response were
combined for further analysis. The effect of DEX was observed
within 3 minutes of drug application. After application of 1 µM
DEX, 6 out of 10 DMV cells (60%) responded with increase of
frequency from 2.5±0.4 Hz (range 1.4-4) to 3.5±0.6 Hz (range
2-5.5; P<0.05; n=6). Application of 3 µM DEX resulted in an
increase in mIPSC frequency in 4 out of 5 DMV neurons (80%),
from 3.4±1 Hz (range 1.1–5.1 Hz) to 4.8±1.6 Hz (range 1.5-8
Hz; P<0.05; n=4). Bath application of 10 µM DEX significantly
increased the frequency of mIPSCs in 8 out of 12 (67%) DMV
cells (Figure 1). Under control conditions, the average of
mIPSC frequency was 1.8±0.2 Hz (range 1-2.4 Hz). Mean
mIPSC frequency was increased in the presence of DEX (10
µM) by 115%, to 3.9±0.8 Hz (range 2–8.3 Hz; P<0.05; n=8;
Figure 1). The remaining neurons displayed no significant
changes in mIPSC frequency in response to DEX. In the
continuous presence of DEX, mIPSC frequency returned to
levels similar to pre-application after 8-10 min (p>0.05 versus
control). Overall, there was no effect of DEX on mIPSC
amplitude (p>0.05), suggesting effects on mIPSC frequency
were due to altered GABA release from presynaptic terminals.
Dexamethasone actions are mediated by a
spironolactone/mifepristone sensitive receptor
Antagonists of type I and II corticosteroid receptors blocked
the DEX effect. Spironolactone (1 µM), an antagonist of type I
corticosteroid receptors or mifepristone (1 µM), and antagonist
of type II corticosteroid receptors was applied prior to and
during DEX application. Neither spironolactone (1 µM) nor
mifepristone (1 µM) alone significantly altered the frequency of
mIPSCs, but each prevented the effect of DEX (10 µM; Figure
2). The frequency of mIPSCs was 3.0±0.4 Hz (range 1.1–5.2
Hz) in the presence of spironolactone (1 µM). After bath
application of DEX (10 µM) in the presence of spironolactone
(1 µM) the mean frequency of mIPSCs was 2.9±0.3 Hz (range
1.7–4.4 Hz; P>0.05; n=9). In another group of neurons, the
frequency of mIPSCs was 4.5±1.4 Hz (range 1.5–13 Hz) in the
presence of mifepristone (1 µM) and was 4.9±2 Hz (range 1.1–
17.8 Hz) after addition of DEX (10 µM; P>0.05; n=9). The effect
of DEX was blocked in the presence of antagonists to
corticosteroid receptors.
Dexamethasone actions are mediated by a membrane-
associated receptor
The rapid onset of the DEX effect on mIPSC frequency
suggested a nongenomic mechanism of action, possibly
mediated by a membrane-associated receptor [16].
Experiments were conducted to determine whether the DEX
effect on GABA release could be prevented by reducing the
ability of DEX to cross the cell membrane and act at
intracellular receptors [36]. Bath application of the membrane-
impermeable, BSA-conjugated DEX (10 µM) mimicked the
effect of DEX on mIPSC frequency. Seven out of 11 cells
(64%) responded to application of BSA-conjugated DEX (10
µM) with a significant increase in mIPSC frequency. The
mIPSC frequency increased from 3.3±1 Hz (range 1.1–9 Hz) to
6.9±2.2 Hz (range 4-20 Hz; P<0.05; n=7; Figure 3) in the
presence of BSA-conjugated DEX, with no significant change
in mIPSC amplitude. These results suggested that the DEX
effect occurred subsequent to activation of a receptor
associated with the postsynaptic membrane and did not require
binding to an intracellular receptor.
Rapid glucocorticoid effects in hypothalamic neuroendocrine
neurons are mediated by a G protein-dependent, putative
postsynaptic mechanism involving release of a retrograde
signalling molecule to affect activity at synaptic terminals [16].
We tested for a similar mechanism in the DVM neurons. The G
protein inhibitor, GDP βS (500 µM) was applied intracellularly
via the recording pipette to inhibit G protein-mediated
responses in the recorded neuron. Control experiments were
performed to ascertain any time-dependent effect of GDP βS
(500 µM) on mIPSC frequency in DMV neurons. The frequency
of mIPSC in the first 5 min of obtaining the recording was 4±0.6
Hz (range 2.2–6 Hz). After 15 min, the frequency of mIPSC
was 3.3±0.4 Hz (range 1.7-4.1 Hz; n=5). The GDP βS alone
had no significant effect on mIPSC frequency (P>0.05) and
amplitude was also unaffected. When GDP βS was included
intracellularly in a different set of neurons, application of DEX
(10 µM) was without effect on mIPSC frequency in any
recorded neuron. In the presence of intracellular GDP βS,
mIPSC frequency was 2.5±0.8 Hz (range 0.2–8 Hz). After
application of the DEX, the mean frequency of mIPSCs was
2.2±.08 Hz (range 0.4–8.5 Hz; P>0.05; n=8; Figure 4).
Because the GDP βS activity was likely restricted to the
Dexamethasone-Induced Retrograde Signaling in DMV
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postsynaptic (i.e., recorded) cell, this suggested that the effect
of DEX was dependent on G-protein-mediated activity in the
recorded neuron.
Inhibition of TRPV1 receptors prevented the effect of
DEX
Since blocking activity in the postsynaptic neuron prevented
DEX-induced changes in mIPSC frequency, the DEX effects on
presynaptic GABA release were hypothesized to be mediated
by the actions of one or more retrograde messengers,
consistent with previous reports in the hypothalamus
Figure 1.  Dexamethasone increases mIPSC frequency in DMV neurons.  A. Continuous recording of mIPSCs observed at
holding potential of -10 mV in the presence of tetrodotoxin (TTX; 1 µM). B. Recording of mIPSCs in the same cell after application of
DEX (10 µM). A1 and B1 are temporally-expanded, 2 s sections from boxed areas of traces A and B, respectively. Recording pipette
contained 140 mM Cs+. C. Cumulative frequency plots of the inter-event interval distribution for mIPSCs before and after application
of DEX for the recording in A and B. A significant effect of DEX was detected in this cell using the Kolmogorov-Smirnov (K–S) test
(P<0.05). D. Change in mIPSC frequency observed 3 min after DEX application in DMV neurons that were determined to have
responded to DEX by K–S test (n=8; p<0.05). E. The effect of DEX in responding cells as a function of concentration. The effect of
the highest DEX concentration (10 µM) in the presence of kynurenic acid (KYN; 1 mM) is also shown. Numbers in parentheses
above the bars indicate number of replicates; error bars indicate SE.
doi: 10.1371/journal.pone.0070505.g001
Dexamethasone-Induced Retrograde Signaling in DMV
PLOS ONE | www.plosone.org 4 July 2013 | Volume 8 | Issue 7 | e70505
[16,18,37,38]. Anandamide, a potential retrograde messenger
in the DMV, is an agonist at both CB1 and TRPV1 receptors
[36]. Activation of these receptors has opposing effects on
GABA release in the DMV, with CB1 receptor activation
inhibiting and TRPV1 receptor activation increasing mIPSC
frequency [25,26]. Since the effect of DEX was to increase
mIPSC frequency, and we previously showed that anandamide
could activate TRPV1 receptors on GABAergic terminals [25],
we tested the hypothesis that the DEX-induced increase in
mIPSC frequency was mediated by TRPV1 receptors. To block
TRPV1 activity, a potent and highly selective TRPV1
antagonist, 5'-iRFT (1 µM) was applied prior to and during DEX
Figure 2.  Rapid glucocorticoid effects are prevented by
glucocorticoid receptor blockade.  A. Continuous recordings
of mIPSCs at a holding potential of -10 mV in the presence of
the type I corticosteroid receptor antagonist, spironolactone (1
µM). B. The same cell after co-application of DEX (10 µM). A1
and B1 are temporally-expanded, 2 s sections from boxed
areas of traces A and B (arrows). C. The DEX-induced
increase in mIPSC frequency was never observed in the
presence of type I and II corticosteroid receptors antagonists
spironolactone (1 µM; n=9; p>0.05) or mifepristone (1 µM; n=9;
p>0.05). Error bars indicate SE.
doi: 10.1371/journal.pone.0070505.g002
application. The antagonist alone had no effect on the
frequency of mIPSCs, but completely prevented the effect of
DEX (Figure 5A–D). The frequency of mIPSCs was 3.1±0.7 Hz
(range 0.6–8 Hz) in the presence of 5'-iRFT and 3±0.7 (range
0.6–7.6 Hz) after bath application of DEX (10 µM) in the
continued presence of 5'-iRFT (P>0.05; n = 12). Similarly, no
change in mIPSC frequency was observed when DEX was
applied in the presence of another TRPV1 antagonist, CPZ (10
µM; n=6; P>0.05; Figure 5D). Blockade of TRPV1 receptors
prevented the increase in mIPSC frequency after DEX
application, suggesting that DEX induced the release of an
endogenous vanilloid receptor agonist.
We hypothesized that the facilitatory effect of DEX on GABA
release onto DMV neurons might be negatively modulated by
CB1 receptor-mediated inhibition of GABA release in the same
terminals. Bath application of the CB1 receptor antagonist
AM251 (20 µM) did not alter the DEX effect. Bath application of
DEX (10 µM) in the presence of AM251 produced an increase
in mIPSC frequency in 8 out of 13 neurons (62%), from 4.9±1.2
Hz (range 2-11; n=8) in AM251 to 6.9±1.7 Hz (range 3-14; n=8;
P<0.05; Figure 5E) with the addition of DEX, similar to effects
in the absence of the CB1 receptor antagonist. The effect of
DEX on mIPSC frequency occurred independently of CB1
receptor-mediated activity.
Dexamethasone effects on glutamate release
Enhancement of GABA release by bath-applied capsaicin is
attenuated by ionotropic and metabotropic glutamate receptor
antagonists, suggesting the TRPV1-dependent effect on
mIPSC frequency is mediated in large part by a heterosynaptic,
glutamate-dependent mechanism [25]. In the presence of
kynurenic acid (1 mM) to block ionotropic glutamate receptors,
DEX application (10 µM) resulted in an increase in mIPSC
frequency of 79% (n=5; p<0.05; Figure 1E). This was notably
less robust than the response in the absence of glutamate
receptor blockers (i.e., 115%). Although the difference in
response was not significant (p>0.05), the result suggested
involvement of DEX-induced glutamate release in the
GABAergic response to DEX. To determine if DEX caused a
change in synaptic glutamate release, the effect of DEX on
mEPSC frequency was tested in the presence of picrotoxin
(100 µM), while voltage-clamping the recorded cell at -70 mV.
DEX (10 µM) increased mEPSC frequency from 8.7±2.4 Hz
(range 2.4-16.9 Hz) to 18.0±4.0 Hz (range 6.4-28.8 Hz; 127%
increase; p<0.05), with no change in mEPSC amplitude
(p>0.05). The effect on mEPSC frequency persisted throughout
the DEX application (14.5 ±3.7 Hz at 10 min of continuous
application). Similar to effects on GABA release, glutamate
release was enhanced by DEX. Blockade of ionotropic
glutamate receptors suppressed, but did not eliminate the
effect of DEX on GABA release.
Inhibition of anandamide metabolism and transport
The endogenous cannabinoid, anandamide activates TRPV1
receptors, which leads to facilitation of neurotransmitter release
in the DMV [25] and is therefore also an endogenous vanilloid
agonist candidate. We examined the contribution of proteins
involved in anandamide signalling on the effect of DEX on
Dexamethasone-Induced Retrograde Signaling in DMV
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Figure 3.  The membrane impermeant BSA-conjugated DEX enhanced mIPSC frequency, suggesting activation of a
nonclassical membrane-associated glucocorticoid receptor.  A. Continuous recording of mIPSCs observed at holding potential
of -10 mV. B. mIPSCs recorded after application of a membrane-impermeable, BSA-conjugated DEX (10 µM). A1 and B1 are
temporally-expanded, 2 s sections from boxed areas of traces A and B above (arrows). C. Cumulative plots of the inter-event
interval distribution for mIPSCs before and after application of BSA-conjugated DEX from the recording in A and B (P<0.05; K–S
test). D. Changes in mIPSC frequency in responsive DMV neurons after 3 min application of BSA-conjugated DEX (10 µM; n=7;
p<0.05).
doi: 10.1371/journal.pone.0070505.g003
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mIPSCs. The effect of DEX was tested in the presence of
inhibitors of anandamide metabolism and transport. Bath
application of URB-597 (10 µM), an inhibitor of FAAH, had no
significant effect on mIPSC frequency (n=7; P>0.05). Following
application of DEX (10 µM) in the presence of URB-597, no
significant effect on mIPSC frequency was observed in any
neuron (Figure 6). The frequency of mIPSCs was 3.4±1.5 Hz
(range 0.5–15 Hz) in the presence of URB-597 and was
2.8±1.1 Hz (range 0.3-11.4; P>0.05; n=10) after DEX
application. Inhibiting FAAH activity prevented the effect of
DEX on mIPSC frequency.
The application of an anandamide transporter inhibitor,
OMDM-2 also was without effect on mIPSC frequency (n=6;
P>0.05). Application of DEX (10 µM) in the presence of
OMDM-2 had no significant effect on the frequency of mIPSCs
in any cell (2.4±0.9 Hz, range 0.4–6.1 Hz; n=6; P>0.05; Figure
6). Separate experiments performed using another
anandamide transport inhibitor, O-2093 (10 µM) yielded similar
results. The mean mIPSC frequency was 3.6±0.9 Hz (range
2.1-7.1 Hz) in the presence of O-2093 and was 3.9±0.9 Hz
(range 2-7.2 Hz) after additional application of DEX (P>0.05;
Figure 4.  Blockade of G protein-mediated responses in the recorded neuron prevents the DEX-induced change in mIPSC
frequency.  A. Continuous recordings recording of mIPSCs after loading of the recorded cell with the G protein inhibitor, GDP βS
(500 µM in the recording pipette). B. mIPSCs recorded in the same neuron after application of DEX (10 µM). A1 and B1 are
temporally-expanded, 2 s sections from boxed areas of traces A and B (arrows). C. Cumulative plots of the inter-event interval
distribution for mIPSCs in the GDP βS-loaded cell shown in A and B indicates no effect of DEX (P>0.05; K–S test). D. Graph of
mean mIPSC frequency before and after DEX application in GDP βS-loaded neurons. No effect of DEX was observed in any neuron
(n=13; P>0.05).
doi: 10.1371/journal.pone.0070505.g004
Dexamethasone-Induced Retrograde Signaling in DMV
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Figure 6). Blocking anandamide transport prevented the
enhancement of mEPSC frequency by DEX.
Discussion
Fast synaptic input to preganglionic parasympathetic motor
neurons of the DMV is primarily GABAergic and glutamatergic
[2,35]. Whereas glutamatergic input is thought to play a
relatively minor role in regulating the ongoing activity of DMV
Figure 5.  The glucocorticoid-induced increase in mIPSC frequency is blocked by TRPV1 antagonists.  A. Continuous
recordings of mIPSCs at a holding potential of -10 mV in the presence of the TRPV1 antagonist, 5’-iodoresiniferatoxin (5’-iRFT; 1
µM). B. The same cell after application of DEX (10 µM). A1 and B1 are temporally-expanded, 2 s sections from boxed areas of
traces A and B (arrows). C. Cumulative frequency plots of data from the recording shown in A and B indicate no DEX-induced
change in mIPSC inter-event interval (P>0.05; K–S test). D. The DEX-induced increase in mIPSC frequency was blocked with bath
pre-application of 5’-iRFT (n=12; p>0.05) or capsazepine (CPZ; 10 µM; n=6; P>0.05). E. Application of DEX increased mIPSC
frequency in the presence of the cannabinoid type 1 receptor antagonist, AM251 (20 µM; n=8; p<0.05).
doi: 10.1371/journal.pone.0070505.g005
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neurons, GABA release is tonic and contributes significantly to
activity levels of preganglionic DMV neurons [39,40]. A variety
of neuromodulatory substances can affect GABAergic synaptic
input to these cells, including candidate retrograde messengers
like anandamide [25,26]. Rather than being stored and
released from vesicles, anandamide and other
endocannabinoids are instead synthesized in the cell
membrane and released locally upon formation. They then act
as retrograde signals that modify synaptic inputs, typically by
binding to receptors on presynaptic terminals [41]. The release
of endocannabinoids can be caused by a variety of different
stimuli, including by activity-dependent mechanisms [22],
neuromodulator-mediated G protein-coupled receptor
activation [42], and rapid steroid actions [16]. The present
findings, together with previous reports on activity-dependent
endocannabinoid effects [31], indicate these mechanisms also
affect GABA release in the DMV.
In the DMV, exogenously-applied anandamide binds to both
CB1and TRPV1 receptors located on presynaptic axon
terminals, where their activation leads to a mild suppression or
profound enhancement, respectively, of neurotransmitter
release [25,26]. Anandamide and several other
endocannabinoid ligands are also classified as ‘endovanilloids’,
based on their ability to activate TRPV1 receptors [36]. In fact,
transient anandamide application principally acts at TRPV1
receptors on synaptic terminals in the DMV to potently increase
GABA release, an effect that involved a heterosynaptic,
glutamate-mediated mechanism [25]. Anandamide acts in the
vagal complex at both CB1 and TRPV1 receptors and can
affect visceral function by modulating GABA and glutamate
release [9,43]. Administration of anandamide or capsaicin into
the fourth ventricle increases gastric acid secretion due to
TRPV1-modulated modulation of central synaptic mechanisms
Figure 6.  Blockade of anandamide metabolism or
transport prevented the effect of DEX.  The effect of DEX on
mIPSC frequency was prevented in the presence of the fatty
acid amide hydrolyse (FAAH) inhibitor, URB597 (10 µM; n=11;
P>0.05). Blocking anandamide transport with OMDM-2 (10 µM;
n=6; P>0.05) or O-2093 (10 µM; n=6; P>0.05) also prevented
the effect of DEX on mIPSC frequency.
doi: 10.1371/journal.pone.0070505.g006
[44]. Thus, a role for anandamide as an endovanilloid in the
vagal complex is supported by the present findings.
Rapid effects of glucocorticoid receptor activation in the
hypothalamus has been demonstrated to be mediated by
neuron- and perhaps synapse-specific release of retrograde
messengers, including anandamide, whose release is
stimulated by binding of a putative membrane-associated
glucocorticoid receptor [16,37,38,45]. Glucocorticoids rapidly
suppress glutamate release in hypothalamic neuroendocrine
neurons via a CB1 receptor-dependent mechanism [16] and
enhance GABA release through retrograde nitric oxide
signaling [38]. Glucocorticoid effects on glutamate release in
gastric-related, preautonomic hypothalamic neurons are
biphasic, involving both TRPV1 and CB1 receptor activation
[18]. We found that DEX, a glucocorticoid receptor agonist,
rapidly enhanced GABAergic input to DMV neurons in a
concentration-related fashion. The effect was blocked by both
spironolactone and mifepristone, consistent with activation of
glucocorticoid receptors. We did not differentiate the effect on
individual receptors; concentrations of both antagonists may
have been high enough in vitro to block either glucocorticoid
type I or II receptors. The enhanced mIPSC frequency
represents an increase in synaptic GABA release from
terminals rather than increased action potential activity in
afferent GABA neurons, since sodium channels were
continually blocked with TTX. Thus, the enhancement of
mIPSC frequency was likely due to effects at the terminals of
afferent neurons. The DEX-induced increase in GABA release
was insensitive to blockade of CB1 receptors, but was
prevented by selective antagonism of TRPV1 receptors with
either capsazepine or 5’-iRFT. Thus, the ability of DEX to
enhance GABA release depended upon both glucocorticoid
receptor binding and TRPV1 receptor activation.
In the DMV, effects on GABA release of exogenously applied
TRPV1 agonists like capsaicin were significantly, but not
completely, reduced in the presence of glutamate receptor
antagonists within five minutes of application. This suggested
that TRPV1 agonists bound receptors on glutamatergic
terminals to increase glutamate release, which
heterosynaptically increased GABAergic synaptic inhibition
[25]. Here, we found that DEX increased glutamate release in a
sustained fashion and that DEX effects on GABA release were
present, but somewhat attenuated, in the presence of
ionotropic glutamate receptor blockade. These findings are
consistent with the hypothesis that DEX leads to activation of
TRPV1 receptors on glutamatergic terminals, resulting in a
degree of heterosynaptic enhancement of GABA release in the
DMV. Notably, the DEX-induced increase in GABA release was
maintained in the presence of kynurenic acid, consistent with
additional activation of TRPV1 receptors located on GABAergic
terminals. Effects of retrogradely-released endocannabinoids in
other brain areas are typically highly localized, resulting in
synapse-specific modulation of neurotransmitter release
[38,46]. That the effect appeared to be less dependent on
heterosynaptic mechanisms than for applied agonists could
reflect the highly localized release and function of retrograde
messengers.
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It is well-established that TRPV1 receptors on terminals of
glutamatergic primary viscerosensory vagal afferents modulate
vagal terminal activity and also mediate asynchronous
glutamate release in the NTS [27–29]. Vagal afferents are also
known to synapse on dendrites of DMV neurons in the rat [47].
Further, NTS neurons likely also express TRPV1 message
[30], and functional data support the hypothesis that TRPV1
receptors are located on terminals of NTS neurons [25]. While
the precise location of TRPV1 receptors that mediate the
enhancement of GABA release by DEX in the DMV is
uncertain, it is possible that receptors on primary
viscerosensory afferents and/or glutamatergic and GABAergic
terminals of NTS neurons contacting DMV cells contribute to
the response.
The nature of the DEX effect suggested activity at a
membrane receptor, similar to that in previous studies of rapid
glucocorticoid-induced effects on synaptic input [16]. In support
of this, the effect of DEX was mimicked by application of BSA-
conjugated DEX, which was assumed to be less able to cross
the cell membrane and bind canonical intracellular receptors. In
several other brain areas, a membrane-bound glucocorticoid
receptor has been proposed, based on electrophysiological or
anatomical data [16,19,20]. Similar to hypothalamic neurons,
the effect of DEX-induced enhancement of mIPSC frequency in
the DMV was prevented when GDP βS was used intracellularly
to block G protein activity in the recorded neuron. This
observation suggests that the effects seen here are secondary
to DEX-induced activation of G protein-coupled receptors on
the recorded DMV neuron. Together, these data are consistent
with the hypothesis that DEX activates a G protein-coupled,
membrane-associated receptor on DMV neurons, activation of
which leads to a TRPV1-dependent enhancement of GABA
release in the DMV.
TRPV1 receptors at synaptic terminals are activated by a
number of stimuli, including pH, temperature, and exogenous
application of capsaicin or anandamide [25]. In the DMV, CB1
receptor activation diminished synaptic activity moderately over
a period of several minutes [26] and after strong depolarization
of DMV neurons [31], whereas activation of TRPV1 receptors
on presynaptic terminals resulted in a rapid and potent
enhancement of GABA release [25]. These effects were
recapitulated by anandamide application [25], suggesting that a
single endocannabinoid ligand could induce increases and/or
decreases in synaptic input. Other retrogradely-released
substances have been identified that could act as putative
endovanilloids to affect changes in presynaptic terminals
[36,43], including in the vagal complex [24]. Several candidates
are metabolites of eicosanoid-derived endocannabinoids,
including those derived from anandamide [36]. The rapid
effects of DEX on TRPV1 receptors seen here could thus be
mediated by an anandamide metabolite or more directly by
released anandamide or some other related eicosanoid.
Unexpectedly, we did not detect a decrease in synaptic input
after DEX application in the presence of TRPV1 antagonists,
and blockade of CB1 receptors with AM-251 had little effect on
mIPSC frequency or on the DEX-induced increase in GABA
release. These data suggest little, if any, CB1 receptor-
mediated effect of DEX-induced retrograde messenger release.
This could be for several reasons, including that DEX induced
the release of an agonist with little activity at CB1 receptors.
Another is that DEX-induced activity resulted in low
anandamide concentrations; CB1R-mediated effects of applied
anandamide are not as robust as are TRPV1-mediated effects
at the same concentration [25]. Additionally, the DEX-mediated
release of anandamide or other messenger could conceivably
occur selectively near synaptic terminals containing TRPV1,
but not CB1, receptors. Such synapse-specific release of
retrograde messengers by DEX or membrane depolarization
has been demonstrated elsewhere in the brain [38,45,48].
Alternatively, the messenger mediating the TRPV1-
dependent enhancement of GABA release by DEX could be
one of anandamide’s metabolites. The effects of DEX were
abrogated by inhibiting activity of FAAH, the enzyme
responsible for metabolic processing of anandamide and
probably other eicosanoids. Blocking anandamide metabolism
might have been expected to increase the extracellular
concentration of the agonist, with the expected result that DEX
effects would be enhanced. This was not the case; inhibiting
FAAH prevented any DEX-induced change in mIPSC
frequency. Metabolites of anandamide, including arachidonic
acid and it’s derivatives have been previously hypothesized to
be candidate ‘endovanilloid’ retrograde messengers [36]. Since
preventing metabolism with URB597 prevented the effect of
DEX, this suggests the possibility that a metabolite of
anandamide (or other endocannabinoid that is metabolized by
FAAH) may be the agonist that binds TRPV1 in this system.
Blocking putative anandamide transport with either OMDM-2
or O-2093 might also be expected to increase the agonist
effect by preventing reuptake into the recorded DMV cell or
nearby neural or glial elements, allowing the agonist to
accumulate extracellularly. Notably, the agonist binding site on
the TRPV1 receptor is intracellular. Passive or facilitated
diffusion or active transport have all been proposed as
mechanisms that might allow the agonist passage across the
membrane to reach the TRPV1 binding site [36]. In addition to
blocking reuptake, blocking transporter function should reduce
anandamide transport across the afferent nerve terminal
membrane, thereby limiting its access to the intracellular
TRPV1 binding site. In support of this mechanism in the DMV,
anandamide uptake inhibitors prevented the DEX effect on
GABA release.
Endogenous anandamide release results following strong
depolarization of DMV neurons, resulting in depolarization-
induced suppression of inhibition (i.e., DSI) [31]. Anandamide
binding to CB1 receptors in the DMV is proposed as the
mediator of that effect, with no detectable TRPV1-mediated
activity. The effect of DEX in the present study was affected by
inhibition of specific transporters and metabolism of
anandamide, suggesting anandamide (or another eicosanoid -
derived endocannabinoid with similar mediators of metabolism
and transport) as a logical mediator of the mIPSC
enhancement by DEX. However, we observed little evidence of
CB1 receptor involvement in the response to DEX. It is
possible that differences in recording conditions underlie the
different responses. For example, the DSI effect observed
previously [31] was observed in the presence of a high glucose
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concentration (i.e., 25 mM), which was more than double that
used herein. Prolonged elevation in glucose concentration in
mice with type 1 diabetes induces internalization of TRPV1
receptors in the DMV [49], resulting in elimination of their
function. If similar receptor internalization resulted during the
course of experiments demonstrating DSI, then any TRPV1-
mediated effect of depolarization could have been reduced in
the presence of the elevated glucose used in those studies.
Alternatively, the methods of evoking release (brief
depolarization versus DEX application) could result in different
pools of endocannabinoid being released and acting on
separate afferent terminals [48]. Here, analyses of mIPSCs
were performed at a holding potential of -10 mV, which allowed
isolation of mIPSCs without the necessity of blocking glutamate
receptors, which reduces TRPV1-mediated GABA release [25].
Effects of DEX were evident at this potential, and TPRV1
antagonists alone had no effect on mIPSC frequency,
suggesting that continuous depolarization may not have
induced continual release of a TRPV1 agonist. Alternatively,
TRPV1-mediated effects of tonic depolarization on GABA
release may have subsided, leaving a separate DEX-induced
release of agonist. Our results are consistent with the
hypothesis that DMV cells release anandamide or other related
eicosanoid, resulting in a TRPV1-mediated enhancement of
GABA release in the DMV in response to DEX, independent of
DMV neuron depolarization.
Most DMV neurons are preganglionic parasympathetic
neurons that convey information to the digestive system [3].
They tend to exhibit a slow, continuous action potential firing
pattern [3], and their activity is heavily modulated by
GABAergic synaptic input [4]. Glucocorticoids acting in the
CNS are known to affect vagally-mediated metabolic and
autonomic functions [9], and effects of glucocorticoids in the
DMV include altered blood pressure, decreased emetic
responses, and increased gastric acid secretion
[10–12,43,44,50]. The effects of DEX on synaptic input to DMV
neurons observed here are consistent with many of these
effects. The highly regulated feedback facilitation of inhibitory
input caused by DEX-induced TRPV1 activation would tend to
make DMV cells less susceptible to stimuli that suppress
synaptic inhibition and thus stabilize vagal motor output. Loss
of this facilitation, as occurs in diabetic animals [49], could
significantly influence important autonomic visceral functions.
Further study of visceral system-specific effects of DEX activity
in the dorsal vagal complex may offer improved understanding
of glucocorticoid modulation of autonomic functions, especially
those related to gastrointestinal function, digestion, and
feeding.
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